Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

777.66
+4.790.62%
Post-market: 778.801.14+0.15%19:31 EDT
Volume:3.30M
Turnover:2.58B
Market Cap:737.02B
PE:63.28
High:792.69
Open:774.85
Low:768.80
Close:772.87
Loading ...

Eli Lilly Stock (LLY) Has Price Target Lowered by Analysts at HSBC

TIPRANKS
·
20 May

HSBC Adjusts Price Target on Eli Lilly and Company to $675 From $700, Maintains Reduce Rating

MT Newswires Live
·
19 May

Eli Lilly & Co : HSBC Cuts Target Price to $675 From $700

THOMSON REUTERS
·
19 May

Eli Lilly & Co. Stock Climbs 3.5%, Outperforms Competitors

Dow Jones
·
17 May

Mixed options sentiment in Eli Lilly (LLY), with shares up $16.30 (+2.23%) near $748.09

TIPRANKS
·
16 May

Eli Lilly Shares up 1.7% After Rival Novo Nordisk CEO Steps Down

THOMSON REUTERS
·
16 May

Eli Lilly Shares up 1.8% Premarket After Rival Novo Nordisk CEO Steps Down

THOMSON REUTERS
·
16 May

Soros Fund Management Dissolves Share Stake in Super Micro Computer

THOMSON REUTERS
·
16 May

BRIEF-Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-Editing Therapeutics

Reuters
·
16 May

Eli Lilly, Rznomics Collaborate to Develop RNA-Editing Therapies for Hearing Loss Treatment

MT Newswires Live
·
16 May

Rznomics Enters Global Licensing Agreement With Eli Lilly for Rna-Editing Therapeutics

THOMSON REUTERS
·
15 May

Rznomics: Upfront Payment Was Not Disclosed

THOMSON REUTERS
·
15 May

Rznomics: IF Lilly Exercises All Available Options Under Agreement, Total Deal Value Could Reach More Than $1.3 Bln

THOMSON REUTERS
·
15 May

Analysts Conflicted on These Healthcare Names: Kezar Life Sciences (KZR), Eli Lilly & Co (LLY) and Becton Dickinson (BDX)

TIPRANKS
·
15 May

Eli Lilly & Co. Stock Slides 4.1%, Underperforms Competitors

Dow Jones
·
15 May

Mixed options sentiment in Eli Lilly (LLY), with shares down $-29.65 (-3.97%) near $716.41

TIPRANKS
·
15 May

Roche says Trump's drug price order threatens its $50 billion US investment plans

Reuters
·
14 May

Novo Nordisk and Septerna Say They Will Collaborate on Developing Medicines for Obesity, Type 2 Diabetes

THOMSON REUTERS
·
14 May

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Reuters
·
14 May

Deal Worth up to $2.2 Billion for Septerna, the Companies Say

THOMSON REUTERS
·
14 May